A Historic Combination

For years, clinicians and researchers working in the repurposed drug space have recognized the remarkable — and largely independent — anti-cancer signals emerging from three antiparasitic agents: ivermectin, mebendazole, and fenbendazole. Each has accumulated a growing body of preclinical and emerging clinical evidence pointing toward mechanisms that disrupt cancer cell survival. Until now, patients and practitioners seeking this protocol have had to navigate multiple separate formulations, dosing logistics, and variable product quality.

That changes with the arrival of the world’s first single-capsule triple combination: IVM 15 mg / MEBEN 100 mg / FENBEN 200 mg — precisely dosed, rigorously manufactured, and delivered in one clean, convenient capsule.

“The convergence of three repurposed antiparasitics into a single, purity-verified formulation represents a landmark moment for integrative oncology.”

How Each Compound Contributes

Together, these three compounds create a multi-pathway approach that targets cancer biology from distinct yet complementary angles — a principle that mirrors the logic of modern combination chemotherapy, but within the repurposed, lower-toxicity antiparasitic class.

Purity as a Non-Negotiable Standard

One of the most significant differentiators of this formulation is not just what is in it — but what is not. In an era of growing concern about compounding quality, excipient toxicity, and environmental contaminants, this capsule sets a new benchmark for clean formulation in integrative medicine.

This matters deeply for the patients who need it most. Individuals with cancer often carry a significant toxic burden — compromised detoxification pathways, heightened sensitivity to environmental inputs, and immune systems under strain. Introducing heavy metals, mycotoxins, or synthetic excipients — even in trace amounts — can undermine the very therapeutic goals the protocol is designed to serve. This formulation eliminates that risk entirely.

Why Repurposed Drugs?

The repurposed drug movement in oncology has gained extraordinary momentum over the past decade. Antiparasitic agents — developed and safety-profiled over decades of use in millions of patients — offer a unique advantage: known tolerability profiles, established pharmacokinetics, and dramatically lower cost compared to novel targeted therapies.

Ivermectin, mebendazole, and fenbendazole individually have each become topics of serious academic inquiry in cancer biology. The Care Oncology Clinic protocol, the work of researchers like Dr. Gilles Donadieu, and a growing body of case reports and observational data have pushed these agents from the fringes to the forefront of integrative oncology discussion. This combination capsule is the logical formulation evolution of that movement.

Designed for the Modern Integrative Protocol

Practitioners working with patients on repurposed drug protocols understand the compliance challenge. Asking a patient managing cancer, its treatments, and a complex supplement regimen to additionally juggle three separate antiparasitic compounds — with their own individual dosing windows, food interactions, and sourcing requirements — is a meaningful burden.

Consolidating into a single, precision-dosed capsule removes that friction. It also eliminates the quality uncertainty that plagues the compounding and grey-market sourcing landscape many patients currently navigate. One capsule. Known doses. Verified purity. Dispensed through a trusted clinical channel.